These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 19908925)

  • 1. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.
    Lieu TA; Ray GT; Ortega-Sanchez IR; Kleinman K; Rusinak D; Prosser LA
    Pharmacoeconomics; 2009; 27(12):1005-16. PubMed ID: 19908925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community and patient values for preventing herpes zoster.
    Lieu TA; Ortega-Sanchez I; Ray GT; Rusinak D; Yih WK; Choo PW; Shui I; Kleinman K; Harpaz R; Prosser LA
    Pharmacoeconomics; 2008; 26(3):235-49. PubMed ID: 18282017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
    Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
    BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of herpes zoster vaccine in Canada.
    Najafzadeh M; Marra CA; Galanis E; Patrick DM
    Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
    Le P; Rothberg MB
    Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Rothberg MB; Virapongse A; Smith KJ
    Clin Infect Dis; 2007 May; 44(10):1280-8. PubMed ID: 17443464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
    Annemans L; Bresse X; Gobbo C; Papageorgiou M
    J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
    Olofsson S; Norrlid H; Persson U
    J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferences and Willingness to Pay for Herpes Zoster Vaccination Among Chinese Adults: Discrete Choice Experiment.
    Xia Y; Wang M; Hu M; Wang Y; Yuan B; Zhu D; He P
    JMIR Public Health Surveill; 2024 Aug; 10():e51242. PubMed ID: 39121469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes zoster vaccine: A health economic evaluation for Switzerland.
    Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
    Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.
    Graham J; Mauskopf J; Kawai K; Johnson KD; Xu R; Acosta CJ
    J Manag Care Spec Pharm; 2016 Jul; 22(7):872-88. PubMed ID: 27348287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
    Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
    Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of vaccination against herpes zoster.
    de Boer PT; Wilschut JC; Postma MJ
    Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of the cost effectiveness of herpes zoster vaccination.
    Szucs TD; Pfeil AM
    Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
    You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
    Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.